Benchmark lowered the firm’s price target on Quipt Home Medical (QIPT) to $6 from $7 and keeps a Buy rating on the shares, citing a reduced EBITDA outlook following the fiscal Q4 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QIPT:
- Quipt Home Medical Shows Strong 2024 Financial Growth
- Quipt Home Medical reports Q4 revenue $61.3M vs $59.6M last year
- Options Volatility and Implied Earnings Moves Today, December 16, 2024
- QIPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quipt Home Medical price target lowered to C$7.50 from C$8.50 at Stifel